- Home
- CCM vs CVKD Comparison
CCM vs CVKD Comparison
Compare CCM & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- CVKD
- Stock Information
- Founded
- CCM 1997
- CVKD 2022
- Country
- CCM China
- CVKD United States
- Employees
- CCM N/A
- CVKD N/A
- Industry
- CCM Medical/Nursing Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- CCM Health Care
- CVKD Health Care
- Exchange
- CCM Nasdaq
- CVKD Nasdaq
- Market Cap
- CCM 33.3M
- CVKD 29.5M
- IPO Year
- CCM 2009
- CVKD 2023
- Fundamental
- Price
- CCM $5.25
- CVKD $11.49
- Analyst Decision
- CCM
- CVKD Strong Buy
- Analyst Count
- CCM 0
- CVKD 1
- Target Price
- CCM N/A
- CVKD $32.00
- AVG Volume (30 Days)
- CCM 16.4K
- CVKD 37.7K
- Earning Date
- CCM 04-25-2025
- CVKD 08-06-2025
- Dividend Yield
- CCM N/A
- CVKD N/A
- EPS Growth
- CCM N/A
- CVKD N/A
- EPS
- CCM N/A
- CVKD N/A
- Revenue
- CCM $52,603,198.00
- CVKD N/A
- Revenue This Year
- CCM N/A
- CVKD N/A
- Revenue Next Year
- CCM N/A
- CVKD N/A
- P/E Ratio
- CCM N/A
- CVKD N/A
- Revenue Growth
- CCM N/A
- CVKD N/A
- 52 Week Low
- CCM $3.80
- CVKD $5.70
- 52 Week High
- CCM $10.77
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- CCM 40.52
- CVKD 43.82
- Support Level
- CCM $5.04
- CVKD $10.45
- Resistance Level
- CCM $6.85
- CVKD $11.98
- Average True Range (ATR)
- CCM 0.82
- CVKD 0.82
- MACD
- CCM 0.03
- CVKD 0.01
- Stochastic Oscillator
- CCM 3.66
- CVKD 32.64
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.